TERN-601
Sources
registry, as of 2026-08-10Stale
https://clinicaltrials.gov/study/NCT06854952
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Enrollment 167. Conditions Overweight or Obesity. This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity. deaths TERN-601 250 mg 0 nausea TERN-601 250 mg 16 vomiting TERN-601 250 mg 2 diarrhoea TERN-601 250 mg 4 deaths TERN-601 500 mg (Slow Titration) 0 nausea TERN-601 500 mg (Slow Titration) 17 vomiting TERN-601 500 mg (Slow Titration) 10 diarrhoea TERN-601 500 mg (Slow Titration) 4 deaths TERN-601 500 mg 0 nausea TERN-601 500 mg 22 vomiting TERN-601 500 mg 13 diarrhoea TERN-601 500 mg 4
ClinicalTrials.gov NCT06854952 protocol and results modules
publication, as of 2026-08-26Stale
https://pubmed.ncbi.nlm.nih.gov/42528333/
Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies. The safety, tolerability, pharmacokinetics, and efficacy of TERN-601, a onc
PMID 42528333